Injectable anabolic-androgenic steroid

Stanozolol (Winstrol Depot)

Stanozolol (Winstrol Depot) has no human half-life in the sources located; the app lists about 24 hours, and the one label located covers 2 mg oral tablets.

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Stanozolol (Winstrol Depot) after one dose: 50% at ~24 h, 25% at 48 h, 12.5% at 72 h.

Drawn from the half-life in the app's model, ~24 h. The model's figures

1

Overview

Sources in this part

  1. 1RxList, 2026

Stanozolol is an anabolic steroid, and the US Winstrol tablet label describes it as "a synthetic derivative of testosterone".1 The label's one listed use is hereditary angioedema, where the tablets are "indicated prophylactically to decrease the frequency and severity of attacks of angioedema".1 The RxList copy of the label states that the Winstrol brand name is "no longer available" in the United States.1 The app's entry is for an injectable form, Winstrol Depot, listed with intramuscular (IM) as its route. The label located is for oral tablets, and no label for an injectable stanozolol product was located (DailyMed search for "stanozolol" returned 0 labels). The app's notes describe the injectable as an aqueous suspension, historically 50 mg/mL, say the half-life figure comes from steroid reference texts and not a published human pharmacokinetic study, and call the half-life and the peak time modelled. The human studies identified for stanozolol are in hereditary angioedema, chronic urticaria and myelodysplastic syndrome, and all used oral doses or did not state the route in the record read. The app grades the evidence for this entry as moderate.

2

How it works

The label states that "Anabolic steroids are synthetic derivatives of testosterone" and that that "Complete dissociation of anabolic and androgenic effects has not been achieved" in the class.1 Sheffer and colleagues describe stanozolol as "an inexpensive anabolic steroid with a 30:1 anabolic:androgenic ratio".2 The label says the class "suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testes".1 The label names the drug's chemical structure as a 17-methyl compound and lists "17-alpha-alkylated androgens" as a group that causes cholestatic hepatitis and jaundice "at relatively low doses".1 In hereditary angioedema, the label describes a deficient or nonfunctional C1 esterase inhibitor (C1 INH) and states that in "small scale clinical studies" stanozolol was "effective in controlling the frequency and severity of attacks of angioedema and in increasing serum levels of C1 INH and C4".1 Sheffer and colleagues report that the rises in C1 inhibitor function and C4 on maintenance therapy "remained below the lower limit of normal range".2 The label adds that the drug "is not effective in stopping HAE attacks while they are under way".1 The app's notes state that stanozolol does not undergo aromatization; none of the fetched texts discusses aromatization of stanozolol.

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~24 h
Bioavailability
95%
Typical dose
150–350 mg/week
Route
IM
Time to peak
~8 h

The second column of the table holds the app's own figures, shown beside what the sources report.

Table 3.1Half-life and pharmacokinetics6 rows
ParameterApp's figureReported in the sources
Half-life~24 h (the app's notes give about 9 h for oral stanozolol)No half-life for stanozolol was located in the label text or in the PubMed records read; the app's notes say the figure comes from steroid reference texts
Absorption half-life2.5 hNo figure located
Bioavailability95%No figure located; the label text read gives none
Time to peak~8 hNo figure located; the app's notes call it modelled
Duration48 hNo figure located
ModelOne-compartmentNot applicable to the sources read

The label text read for oral tablets contains no pharmacokinetic section, so the table has no label figure to set beside the app's figures. The level chart is left out because no cited source reports a dosing interval with a half-life for stanozolol.

4

Human studies

The studies below are in hereditary angioedema, chronic urticaria and high-risk myelodysplastic syndrome. The records read state no use of the injectable aqueous suspension, and none states doses in the app's typical-dose range.

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Sheffer and colleagues, Journal of Allergy and Clinical Immunology, 19812Dose-response series with no comparison group described; NIH grants listed12 male and 15 female patients with biochemically proven hereditary angioedema20.5 to 2 mg daily (4 mg a day also studied); 2 years2Attacks per weeks of therapy 1/14.6, 1/7.2 and 1/8.2 wk at 2, 1 and 0.5 mg daily; menstrual abnormalities and virilization in four females, raised CPK in five males2
Parsad and colleagues, Journal of Dermatology, 20013Randomised, double-blind, placebo-controlled; funding not stated in the record58 patients with refractory chronic idiopathic urticaria; 26 and 24 evaluable32 mg stanozolol twice daily plus cetirizine 10 mg daily, against cetirizine plus placebo; 12 weeks3Marked to complete resolution in 17 of 26 against 7 of 24; adverse event numbers not given in the record3
Liu and colleagues, International Journal of Hematology, 20214Clinical trial; groups of 21 and 41; randomisation not described in the record; Chinese public research grants listed62 patients (median age 66 years) with high-risk MDS in at least partial remission after 4 cycles of decitabine4Stanozolol plus decitabine against decitabine alone, maintenance; median 6 and 5 cycles; dose not given in the record4Progression-free survival 15.0 against 9.0 months (HR 0.35, 95% CI 0.19-0.63, p = 0.0005); overall survival 21.0 against 15.0 months (HR 0.73, 95% CI 0.39-1.37, p = 0.33)4
Sloane and colleagues, Journal of Allergy and Clinical Immunology, 20075Questionnaire, examination, blood tests and liver ultrasound in patients who continued therapy; no comparison group21 patients with hereditary angioedema treated for 20 to 40 years5Initial minimal effective dosage 0.5 to 2.0 mg daily, with most reducing dose and frequency over time5Treatment-related symptoms in 10 of 21; no persistent liver enzyme abnormalities; reduced HDL in 5, elevated triglycerides in 25
Riedl, Annals of Allergy, Asthma and Immunology, 20156Systematic review of androgens (danazol, stanozolol and androgen search terms) in hereditary angioedema63 of 153 PubMed citations contained relevant information6Not applicable; no time limit on the search6Fifteen level-of-evidence 2 studies and multiple level 4 reports confirmed a high level of prophylactic efficacy for androgen therapy, with occasional reports of poor response; results are for androgens as a group6

No registered controlled trial of stanozolol was identified in a ClinicalTrials.gov search for "stanozolol", which returned one study titled "Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia".

Deeper analysis: Sheffer and colleagues, hereditary angioedema, 1981

Sheffer, Fearon and Austen gave stanozolol to 12 male and 15 female patients over 2 years to assess dose, clinical response, side effects and complement abnormalities, according to the PubMed record of their 1981 paper.2 The authors report that "All 27 patients attained the minimal effective dose, ranging from 0.5 to 2 mg daily, which controlled the frequency and intensity of symptoms with minimal side effects".2 Attack frequencies were 1/14.6, 1/7.2 and 1/8.2 per week of therapy at daily maintenance doses of 2, 1 and 0.5 mg; the record gives no placebo or untreated comparison.2 Side effects with maintenance therapy were menstrual abnormalities and virilization in four females and raised serum creatine phosphokinase in five males.2 In six patients on maintenance doses, serum testosterone, free thyroxin and thyroxin binding globulin (four males) and estradiol, progesterone, T4 and TBG (two females) were normal, with slightly low progesterone and TBG in two females who had normal menstrual cycles.2 The authors found that "Higher doses of stanozolol (4 mg/day), which caused greater immunochemical responses, were unnecessary for control of clinical disease and were unjustified for chronic therapy because of more frequent side effects".2 The PubMed record lists grants from NIAID, NIH HHS and NIADDK, NIH HHS and gives no statement of limitations or author ties to a manufacturer.2

Deeper analysis: Parsad and colleagues, chronic urticaria, 2001

Parsad, Pandhi and Juneja, of the Department of Dermatology at the Postgraduate Institute of Medical Education and Research, Chandigarh, India, tested stanozolol as an add-on to an H1 antihistamine in refractory chronic idiopathic urticaria.3 Group A received 2 mg stanozolol twice daily with cetirizine 10 mg daily and group B received cetirizine and placebo tablets twice daily.3 Of 58 patients enrolled, 26 in group A and 24 in group B could be evaluated, so 8 were not among those evaluated, and the authors also report an intention-to-treat analysis.3 At 12 weeks, 17 patients in group A showed "marked to complete resolution as compared to 7 patients in group B", with a "highly significant decrease in mean severity score at 12 weeks" in group A.3 The authors conclude that stanozolol is "an effective and safe adjuvant therapy for treatment of chronic refractory urticaria", yet the record gives no adverse event counts, no stated limitations and no funding statement.3

Deeper analysis: Liu and colleagues, high-risk myelodysplastic syndrome, 2021

Liu and colleagues, from Tianjin Medical University General Hospital and other Chinese hematology departments, wrote that "It is unknown whether adding stanozolol to decitabine for maintenance can further improve progression-free survival".4 They compared 21 patients given stanozolol with decitabine and 41 given decitabine alone, after at least partial remission following 4 cycles of decitabine.4 Progression-free survival was longer with stanozolol (15.0 against 9.0 months, hazard ratio 0.35, 95% CI 0.19-0.63, p = 0.0005), but overall survival was "not significantly prolonged" (21.0 against 15.0 months, HR 0.73, 95% CI 0.39-1.37, p = 0.33).4 Severe neutropenia during maintenance was less frequent with stanozolol (76.2% against 95.1%, p = 0.039).4 The record lists grants from the National Natural Science Foundation of China and other public funds, does not describe how patients were allocated to groups, and gives no stanozolol dose, no liver or lipid results and no stated limitations.4

Deeper analysis: Sloane and colleagues, long-term safety, 2007

Sloane, Lee and Sheffer, with Sloane at Harvard Medical School and Brigham and Women's Hospital, noted that "the side-effect frequencies in patients receiving long-term treatment are relatively less well characterized".5 They surveyed patients who "continued stanozolol therapy since 1987", so those who stopped earlier are not in the 21 patients reported.5 Treatment-related symptoms developed in 10 of 21 patients, "No interruption in stanozolol therapy was required because symptoms subsided with a reduction in the stanozolol dosage", and the listed effects were hirsutism, weight gain, menstrual irregularities or postmenopausal bleeding, acne and mood changes.5 "Liver enzyme assays revealed no persistent abnormalities", liver ultrasounds in 8 patients showed 3 abnormalities "deemed unrelated to therapy", five patients had a reduced high-density lipoprotein and two had elevated triglycerides.5 The authors conclude that "Stanozolol is a safe and effective drug for the long-term management of hereditary angioedema", with the implication that patients be "closely supervised with routine clinical, biochemical, and radiologic assessments".5 The PubMed record gives no funding statement and no stated limitations.5

5

Doses reported in studies and on labels

The label doses are for oral tablets and the Parsad trial used tablets; the Sheffer, Sloane and Liu records do not state the route, and the app's own range is for the injectable.

Table 5.1Doses reported in studies and on labels6 rows
SourceDose reportedPopulation and comparatorReference
Winstrol tablet label, starting regimen2 mg three times a day, then reduced at intervals of one to three months to a maintenance dosage of 2 mg a day; some patients managed on 2 mg on alternate daysHereditary angioedema; "individualized on the basis of the clinical response"1
Sheffer 19810.5 to 2 mg daily as the minimal effective dose; 4 mg/day studied and called unnecessary27 patients with hereditary angioedema, 2 years; no comparison group described2
Sloane 20070.5 to 2.0 mg daily as the minimal initial effective dosage21 patients with hereditary angioedema treated for 20 to 40 years; no comparison group5
Parsad 20012 mg twice daily with cetirizine 10 mg daily, 12 weeks58 enrolled with refractory chronic urticaria; against cetirizine plus placebo3
Liu 2021Dose not given in the record; with decitabine 20 mg/m2 days 1-5 for the preceding 4 cycles62 patients with high-risk MDS; against decitabine alone4
The app's typical range150 to 350 mg/week by IM injection, which the app's notes call the non-medical weekly doseNo label or study located for this rangeApp entry

The app's range of 150 to 350 mg a week differs from the label figures: the label's starting regimen of 2 mg three times a day is 42 mg a week, and its maintenance dosage of 2 mg a day is 14 mg a week.1 The label adds that the use of anabolic steroids "may be associated with serious adverse reactions, many of which are dose related".1

6

Side effects reported

The label's hepatic entry lists "Cholestatic jaundice with, rarely, hepatic necrosis and death", and states that "Hepatocellular neoplasms and peliosis hepatis have been reported in association with long-term androgenic-anabolic steroid therapy".1 The label also lists reversible increases in bilirubin, SGOT and alkaline phosphatase.1 Other label entries include, in postpubertal men, "Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritability", and in women "Clitoral enlargement, menstrual irregularities".1 The label lists gynecomastia, acne, edema with retention of serum electrolytes, decreased glucose tolerance and raised creatinine phosphokinase, and states that "Some virilizing changes in women are irreversible even after prompt discontinuance of therapy".1 In children the label lists "Premature closure of epiphyses" and states that the safety and efficacy of the drug in children with hereditary angioedema "have not been established".1 The label also lists "Bleeding in patients on concomitant anticoagulant therapy" and says anabolic steroids "may cause suppression of clotting factors II, V, VII, and X".1 Riedl's systematic review of androgens in hereditary angioedema, not of stanozolol alone, lists weight gain, menstrual irregularities, virilization, headaches, myalgias or cramps, mood changes, and elevated creatine phosphokinase, liver function tests and serum lipids as common adverse events.6 It adds that "The risk of adverse events is often correlated with dose and/or treatment duration" and that "Rare cases of hepatic adenomas and hepatocellular carcinoma associated with long-term androgen use often had no preceding changes in liver function test results".6 In a veterinary study, not in people, Harkin and colleagues at Kansas State University gave 18 cats stanozolol 25 mg IM on the first day and then 2 mg orally every 12 hours for 4 weeks, and serum ALT rose in 14 of 18.7 In those cats "All 18 cats survived, and hepatic enzyme activities were normal in all cats tested more than 4 weeks after stanozolol administration was discontinued", while two of three cats treated for gingivitis developed severe hepatic failure.7 Most of the healthy cats and cats with renal failure developed marked inappetence, groomed less and were less active within 7 to 10 days, four cats with high serum ALT after 2 weeks had coagulopathies, and the authors concluded that results suggest stanozolol is hepatotoxic in cats.7 No study of liver effects of intramuscular stanozolol in people was identified in the searches run.

7

Bloodwork and markers

The app lists liver enzymes, lipids, hematocrit, total testosterone and SHBG as markers to monitor for this entry. The label calls for periodic liver function tests because of "the hepatotoxicity associated with the use of 17-alpha-alkylated androgens".1 On lipids, the label says Winstrol "has been reported to lower the level of high-density lipoproteins and raise the level of low-density lipoproteins" and that "These changes usually revert to normal on discontinuation of treatment".1 Its Warnings section describes the lipid changes as potentially "very marked", and Sloane and colleagues recorded reduced HDL in 5 and elevated triglycerides in 2 of 21 long-term patients.1,5 For hematocrit, the label calls for periodic checks of hemoglobin and hematocrit "for polycythemia in patients who are receiving high doses of anabolic steroids".1 For hormones, Sheffer and colleagues report normal serum testosterone in four males on maintenance doses, while the label states the class suppresses pituitary gonadotropic function.2,1 The label adds that androgenic anabolic steroids "may decrease levels of thyroxine-binding globulin".1 None of the fetched texts reports sex hormone binding globulin (SHBG) values for stanozolol.

8

Regulatory and anti-doping status

The 2026 World Anti-Doping Agency Prohibited List places anabolic agents under S1, "PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION)", and states that "Anabolic agents are prohibited" in that class.8 Stanozolol appears by name in the list of anabolic androgenic steroids under S1.1, which applies "When administered exogenously, including but not limited to" the named substances.8 The Winstrol label states that the product "is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and has been assigned to Schedule III".1 The label states that anabolic steroids "have not been shown to enhance athletic ability" in its warnings.1 The label lists the tablets as Pregnancy Category X and states that the drug "is contraindicated in women who are or may become pregnant".1 No regulator's assessment of an injectable stanozolol product was located.

9

Storage and handling

Sources in this part

  1. 1RxList, 2026

The tablet label states "Store at controlled room temperature 15° to 30° C (59° to 86° F)".1 No storage statement for an injectable stanozolol product was located.

10

What is not known

None of the texts read gives a human pharmacokinetic figure for stanozolol, so the app's half-life, absorption half-life, bioavailability, time to peak and duration have no cited figure from a source beside them. No PubMed record was identified for an aqueous suspension of stanozolol given by intramuscular injection, and no controlled trial of the injectable form was identified in PubMed or ClinicalTrials.gov. The human studies that state a dose used 0.5 to 2 mg daily (route not stated in the Sheffer and Sloane records) or 2 mg twice daily as tablets (Parsad), well below the app's 150 to 350 mg a week, and the Liu record gives no stanozolol dose. How the label's liver and lipid findings relate to injected doses in the app's range is not reported in the sources read. The evidence in hereditary angioedema rests on small series and a review of androgens as a group, and the MDS and urticaria results come from one trial each, with no adverse event counts in the urticaria record and only severe neutropenia reported in the MDS record. Sources describing stanozolol aromatization and SHBG changes were not located among the texts read.

What is the half-life of stanozolol injectable (Winstrol Depot)?

The app lists a half-life of about 24 hours, and none of the texts located gives a human half-life for stanozolol to set beside it. The app's notes say the figure comes from steroid reference texts, not from a published human pharmacokinetic study.

Is stanozolol banned by WADA?

Yes, stanozolol is named among the anabolic androgenic steroids on the 2026 WADA Prohibited List, in class S1 that is prohibited at all times.8

Is Winstrol Depot oil-based or water-based?

The app's notes describe it as an aqueous (water-based) suspension, historically 50 mg/mL, and not an oil. No label or regulator document for an injectable stanozolol product was located to confirm this.

Is stanozolol hard on the liver?

The Winstrol tablet label reports "Cholestatic jaundice with, rarely, hepatic necrosis and death", and says hepatocellular neoplasms and peliosis hepatis have been reported with long-term androgenic-anabolic steroid therapy.1 In 21 long-term hereditary angioedema patients, Sloane and colleagues reported "no persistent abnormalities" in liver enzyme assays.5 Liver ultrasounds in 8 of them revealed 3 abnormalities that the authors deemed unrelated to therapy.5

Does stanozolol change cholesterol?

The label states that stanozolol has been reported to lower high-density lipoproteins and raise low-density lipoproteins, and that the changes usually revert to normal on discontinuation of treatment.1 Sloane and colleagues found a reduced high-density lipoprotein in 5 of 21 long-term patients.5

What is stanozolol used for in medicine?

The Winstrol tablet label lists hereditary angioedema, to decrease the frequency and severity of attacks.1 The RxList copy states that the brand name is no longer available in the U.S.1

Is stanozolol a controlled substance in the US?

The Winstrol label states that it is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and assigned to Schedule III.1

Has stanozolol been tested in a randomised trial?

Parsad and colleagues reported a randomised, double-blind, placebo-controlled trial of oral stanozolol with cetirizine in 58 patients with chronic refractory urticaria in 2001.3 In that trial 17 patients in group A showed marked to complete resolution against 7 in group B at 12 weeks, among 26 and 24 evaluable patients.3

13

References

  1. RxList. Winstrol (stanozolol tablets): uses, dosage, side effects, warnings; page reproducing the US prescribing text, read 16 November 2026. RxList label text
  2. Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981;68(3):181-7. PMID 6790595
  3. Parsad D, Pandhi R, Juneja A. Stanozolol in chronic urticaria: a double blind, placebo controlled trial. J Dermatol 2001;28(6):299-302. PMID 11476107
  4. Liu Y, et al. Stanozolol improves the progression-free survival of patients with high-risk myelodysplastic syndrome after decitabine treatment. Int J Hematol 2021;113(6):807-814. PMID 33646527
  5. Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: Safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007;120(3):654-8. PMID 17765757
  6. Riedl MA. Critical appraisal of androgen use in hereditary angioedema: a systematic review. Ann Allergy Asthma Immunol 2015;114(4):281-288.e7. PMID 25707325
  7. Harkin KR, et al. Hepatotoxicity of stanozolol in cats. J Am Vet Med Assoc 2000;217(5):681-4. PMID 10976299
  8. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list